Modality
Bispecific Ab
MOA
BCMA ADC
Target
PSMA
Pathway
Lipid Met
RCCCervical Ca
Development Pipeline
Preclinical
Feb 2019
→ May 2030
PreclinicalCurrent
NCT06576456
1,026 pts·RCC
2019-02→2025-12·Active
NCT06893389
1,317 pts·RCC
2021-01→2030-05·Not yet recruiting
2,343 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-114mo agoInterim· RCC
2030-05-034.1y awayInterim· RCC
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Active
Preclinical
Not yet…
Catalysts
Interim
2025-12-11 · 4mo ago
RCC
Interim
2030-05-03 · 4.1y away
RCC
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06576456 | Preclinical | RCC | Active | 1026 | PASI75 |
| NCT06893389 | Preclinical | RCC | Not yet recr... | 1317 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Tixatapinarof | Recursion | Approved | FGFR |